CBC, CMP, lipids, HbA1c or fasting glucose, CRP, ferritin, vitamin D, thyroid
Based on current clinical trial data, tirzepatide (Zepbound/Mounjaro) at the 15 mg dose produces the highest average weight loss approximately 2022% of body weight, or around 48 lbs on average in the SURMOUNT-1 trial
Cautious re-introduction of these agents may be considered in situations where there is a compelling indication for their use, such as heart failure or chronic kidney disease
Researchers studying the transition between compounds should review the tirzepatide to retatrutide switching protocol and the onset timeline when transitioning between these compounds
This single dose was expected to result in an exposure level within the therapeutic range, with a minimum risk of toxicity, and a similar dose has been tested in a similar DDI trial [19]